This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, Q.-X. Articles by Fuqua, S. A. W. Search for Related Content PubMed PubMed Citation Articles by Zhang, Q.-X. Articles by Fuqua, S. A. W.

An Estrogen Receptor Mutant with Strong Hormone-independent Activity from a Metastatic Breast Cancer¹

Department of Oncology, University Hospital, S-221 85 Lund, Sweden [Q-X. Z, Å. B.], and Department of Medical Oncology, University of Texas Health Science Center, San Antonio, Texas 78284-7884 [D. M. W., S. O., S. A. W. F.]

Thirty tumors from metastatic breast cancer patients were screened for mutations in the estrogen receptor (ER) gene using single-strand conformation polymorphism and sequence analysis. Three missense mutations, Ser47Thr, Lys531Glu, and Tyr537Asn, were identified in these lesions. To investigate these mutated ERs or altered transcriptional activation function, expression vectors containing wild-type (wt) and mutant ERs were constructed and cotransfected with different estrogen response element reporter gene constructs into HeLa cells and MDA-MB-231 human breast cancer cells. The first two ER mutants were similar to wt ER. However, the Tyr537Asn ER mutant possessed a potent, estradiol-independent transcriptional activity, as compared to wt ER. Moreover, the constitutive activity of the Tyr537Asn ER mutant was virtually unaffected by estradiol, tamoxifen, or the pure antiestrogen ICI 164,384. Tyr537 is located at the beginning of exon 8 in the COOH-terminal portion of the hormone-binding domain of the ER, to which dimerization and transcription activation functions have also been ascribed. It has been identified as a phosphorylation site implicated in hormone binding, dimerization, and hormone-dependent transcriptional activity. Our results suggest that the Tyr537Asn substitution induces conformational changes in the ER that might mimic hormone binding, not affecting the ability of the receptor to dimerize, but conferring a constitutive transactivation function to the receptor. If present in other metastatic breast tumors, this naturally occurring ER mutant may contribute to breast cancer progression and/or hormone resistance.

¹ This study was supported by grants from the Swedish Cancer Society, the Medical Faculty of Lunds University, the Gunnar A. E. Nilsson Cancer Foundation, and the Mrs. Berta Kamprad Foundation (to Å. B.). This work was also supported by NIH Grants CA30195 and CA54174, and United States Army Medical Research Defense Contract Postdoctoral Fellowship DAMD17-94-J-4112 (to S. A. W. F.).

² To whom requests for reprints should be addressed, at Department of Medical Oncology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78284-7884. Fax: (210) 567-6687; E-mail: suzanne_fuqua@oncology.uthscsa.edu.

Received 11/ 5/96. Accepted 2/14/97.

This article has been cited by other articles:

				J. Keay, J. T. Bridgham, and J. W. Thornton The Octopus vulgaris Estrogen Receptor Is a Constitutive Transcriptional Activator: Evolutionary and Functional Implications Endocrinology, August 1, 2006; 147(8): 3861 - 3869. [Abstract] [Full Text] [PDF]

				R. J. Pietras Biologic Basis of Sequential and Combination Therapies for Hormone-Responsive Breast Cancer Oncologist, July 1, 2006; 11(7): 704 - 717. [Abstract] [Full Text] [PDF]

				J. H. Kim, M. H. Lee, B. J. Kim, J. H. Kim, S. J. Han, H. Y. Kim, and M. R Stallcup Role of aspartate 351 in transactivation and active conformation of estrogen receptor {alpha} J. Mol. Endocrinol., December 1, 2005; 35(3): 449 - 464. [Abstract] [Full Text] [PDF]

				N. C. Peterson, M. D. Servinsky, A. Christian, Z. Peng, W. Qiu, J. Mann, J. Dicello, and D. L. Huso Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model Carcinogenesis, September 1, 2005; 26(9): 1542 - 1552. [Abstract] [Full Text] [PDF]

				T. R. Pak, W. C. J. Chung, T. D. Lund, L. R. Hinds, C. M. Clay, and R. J. Handa The Androgen Metabolite, 5{alpha}-Androstane-3{beta}, 17{beta}-Diol, Is a Potent Modulator of Estrogen Receptor-{beta}1-Mediated Gene Transcription in Neuronal Cells Endocrinology, January 1, 2005; 146(1): 147 - 155. [Abstract] [Full Text] [PDF]

				A. Ring and M. Dowsett Mechanisms of tamoxifen resistance Endocr. Relat. Cancer, December 1, 2004; 11(4): 643 - 658. [Abstract] [Full Text] [PDF]

				M. H. Herynk and S. A. W. Fuqua Estrogen Receptor Mutations in Human Disease Endocr. Rev., December 1, 2004; 25(6): 869 - 898. [Abstract] [Full Text] [PDF]

				T. Bachleitner-Hofmann, B. Pichler-Gebhard, M. Rudas, M. Gnant, S. Taucher, D. Kandioler, E. Janschek, P. Dubsky, S. Roka, E. Sporn, et al. Pattern of Hormone Receptor Status of Secondary Contralateral Breast Cancers in Patients Receiving Adjuvant Tamoxifen Clin. Cancer Res., November 1, 2002; 8(11): 3427 - 3432. [Abstract] [Full Text] [PDF]

				M. S. Bendre, D. Gaddy-Kurten, T. Mon-Foote, N. S. Akel, R. A. Skinner, R. W. Nicholas, and L. J. Suva Expression of Interleukin 8 and not Parathyroid Hormone-related Protein by Human Breast Cancer Cells Correlates with Bone Metastasis in Vivo Cancer Res., October 1, 2002; 62(19): 5571 - 5579. [Abstract] [Full Text] [PDF]

				H. Lu, T. Higashikata, A. Inazu, A. Nohara, W. Yu, M. Shimizu, and H. Mabuchi Association of Estrogen Receptor-{alpha} Gene Polymorphisms With Coronary Artery Disease in Patients With Familial Hypercholesterolemia Arterioscler. Thromb. Vasc. Biol., May 1, 2002; 22(5): 817 - 823. [Abstract] [Full Text] [PDF]

				A. Koide, S. Abbatiello, L. Rothgery, and S. Koide Probing protein conformational changes in living cells by using designer binding proteins: Application to the estrogen receptor PNAS, January 24, 2002; (2002) 32665299. [Abstract] [Full Text] [PDF]

				S. A. W. Fuqua, C. Wiltschke, Q. X. Zhang, A. Borg, C. G. Castles, W. E. Friedrichs, T. Hopp, S. Hilsenbeck, S. Mohsin, P. O’Connell, et al. A Hypersensitive Estrogen Receptor-{{alpha}} Mutation in Premalignant Breast Lesions Cancer Res., August 1, 2000; 60(15): 4026 - 4029. [Abstract] [Full Text]

				K.-M. Lau, S. C. Mok, and S.-M. Ho Expression of human estrogen receptor-alpha and -beta , progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells PNAS, May 11, 1999; 96(10): 5722 - 5727. [Abstract] [Full Text] [PDF]

				F. C. S. Eng, A. Barsalou, N. Akutsu, I. Mercier, C. Zechel, S. Mader, and J. H. White Different Classes of Coactivators Recognize Distinct but Overlapping Binding Sites on the Estrogen Receptor Ligand Binding Domain J. Biol. Chem., October 23, 1998; 273(43): 28371 - 28377. [Abstract] [Full Text] [PDF]

				A. Koide, S. Abbatiello, L. Rothgery, and S. Koide Probing protein conformational changes in living cells by using designer binding proteins: Application to the estrogen receptor PNAS, February 5, 2002; 99(3): 1253 - 1258. [Abstract] [Full Text] [PDF]